Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 6,681 matching trials from the live ClinicalTrials.gov search.

Filters: Stanford, California Clear all

Conditions: Rheumatoid Arthritis (RA)
Interventions: abatacept, Methotrexate (MTX); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more

Conditions: Indolent Systemic Mastocytosis
Interventions: Avapritinib, Placebo; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Stanford, California + 15 more

Conditions: Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions: Fish Oil, Flaxseed Oil, Placebo; Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: High-Grade Glioma
Interventions: CLR 131; Drug
Lead sponsor: Cellectar Biosciences, Inc.; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: Palo Alto, California • New York, New York • Cincinnati, Ohio + 4 more

Conditions: Acute Respiratory Distress Syndrome
Interventions: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Biological
Lead sponsor: Michael A. Matthay; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: San Francisco, California • Stanford, California • Boston, Massachusetts + 1 more

Conditions: Breast Cancer
Interventions: NACgraft; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose); Biological
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer
Interventions: Oral Triamcinalone; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Nasal Polyps
Interventions: Depemokimab (GSK3511294), Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 26
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more

Conditions: Depression, Bipolar Disorder, Mood Disorders, Insulin Resistance, Depressive Disorder, Major, Depressive Disorder
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 20 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type1 Diabetes Mellitus
Interventions: Klue; Device
Lead sponsor: Stanford University; Other
Eligibility: 13 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Fatigue, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment
Interventions: modafinil, placebo; Drug · Other
Lead sponsor: University of South Florida; Other
Eligibility: 6 Years to 19 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 60
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 53 more

Conditions: Solid Tumors
Interventions: OMP-21M18; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: Greenbrae, California • Stanford, California • Ann Arbor, Michigan

Conditions: Covid19
Interventions: Filtration Fan, Safe-home pamphlet, Mid-week phone call; Device · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: San Mateo, California • Stanford, California

Conditions: AL Amyloidosis
Interventions: NEOD001; Drug
Lead sponsor: Prothena Biosciences Ltd.; Industry
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Stanford, California • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Peripheral T-Cell Lymphoma
Interventions: KW-0761; Biological
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 2 more

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: Up to 3 Months
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions: AOC 1001, Placebo; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more

Conditions: Genetic Counseling Profession
Interventions: Meditation; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 605 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Lymphocytic Leukemia
Interventions: Inotuzumab Ozogamicin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 15
States / cities: Duarte, California • Palo Alto, California • Stanford, California + 7 more

Conditions: Heart Transplant, Pediatric Heart Transplant, Rejection, Cardiac MRI, Cell Free DNA
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 6 Years to 25 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 22
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 16 more

Conditions: HIV Infections
Interventions: Lymphocytes, Activated; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Stanford, California

Conditions: Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Localized Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Interventions: Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Vincristine Sulfate; Drug · Biological · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 49 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 196
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 142 more

Conditions: Neural Tube Defects, Anemia, Leukemia, Myeloid, Bone Marrow Transplant Failure, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders
Interventions: CIK cells, Cyclosporine, Mycophenolate Mofetil, Thymoglobulin, Total Lymphoid Irradiation (TLI); Drug · Radiation
Lead sponsor: Everett Meyer; Other
Eligibility: 50 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stanford, California

Search by objective public record fields.

Phase IIIB Subcutaneous Abatacept Monotherapy Study

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

Effects of Omega-3 Fatty Acids on Markers of Inflammation

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

A Pilot Study Evaluating Oral Triamcinalone in Patients With Androgen Independent Prostate Cancer

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

Insulin Resistance in Patients With Major Depression

Real-time Reminders To Decrease Late or Missed Meal Boluses

Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

Cluster-Randomized Trial of Air Filtration and Ventilation to Reduce Covid19 Spread in Homes

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma

Pharmacology of Aminophylline for Acute Kidney Injury in Neonates

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Me-GC: A Randomized Controlled Trial of Meditation for Genetic Counselors

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Non-invasive Prediction of EArly Cardiac rEjection

A Study of Cytotoxic T Lymphocyte (CTL) Therapy in HIV-Infected Patients

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders